New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:08 EDTENDP, BDSIBioDelivery Sciences reports cash at end of FY12 $63.2M vs. $10.8M
BioDelivery Sciences (BDSI) ,BDSI's, research and development expenditures increased from $20.8M in 2011 to $35.4M in 2012. Revenues recognized in 2012 were $54.5M, including $35.8M from Endo (ENDP) and $17.5M previously deferred revenue associated with the BDSI commercialization agreement with Meda for BDSI's FDA approved product ONSOLIS. At the end of 2012, BDSI had $9.2M in deferred revenue associated with Endo, which will be recognized through 2013 and into early 2014 as clinical trials progress. BDSI reported net income of $1.7M or 5c per share for the twelve months ending December 31. That compares to a net loss of $23.3M or (82c) per share in 2011. At the end of 2012, BDSI had $63.2M in cash compared to $10.8M at December 31, 2011.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTENDPPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:11 EDTENDPTrimel announces license agreement with Endo for NATESTO
Subscribe for More Information
07:02 EDTENDPEndo acquires rights to Natesto testosterone nasal gel
Endo announced the acquisition of rights to Natesto, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporatio. Natesto™ was approved by the FDA in May of 2014. Under the terms of the agreement Trimel will receive an upfront payment of $25M and could receive additional payments upon the achievement of certain regulatory and sales milestones. Additionally, Trimel will be responsible for the manufacture and supply of Natesto and Endo will pay a tiered supply price for the product. Endo expects the transaction to close in early 2015. Under the terms of the agreement, Endo receives sole and exclusive commercial rights to the Natesto product in the US and Mexico. In addition, Endo will collaborate on all regulatory and clinical development activities in coordination with Trimel.
November 21, 2014
14:51 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
November 20, 2014
07:33 EDTENDPEndo launches generic version of Hoffmann-La Roche's Valcyte
Endo's Qualitest subsidiary has launched a generic version of Hoffmann-La Roche's Valcyte. For the 12 months ending September 30, Valcyte had total U.S. sales of approximately $440M, according to IMS Health data.
November 19, 2014
10:21 EDTENDPHigh option volume stocks
Subscribe for More Information
07:33 EDTENDPEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
07:09 EDTBDSIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 14, 2014
09:38 EDTENDPJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use